Nahdi Medical Company (4164.SR)
SAR 120.8
(0.0%)
SAR 120.8
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.17 Billion SAR | 0.57% |
| 2022 | 1.16 Billion SAR | -14.05% |
| 2021 | 1.35 Billion SAR | 10.04% |
| 2020 | 1.23 Billion SAR | 1.43% |
| 2019 | 1.21 Billion SAR | 0.0% |
| 2018 | - SAR | 0.0% |
| 2017 | - SAR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.27 Billion SAR | 6.55% |
| 2024 Q1 | 1.19 Billion SAR | 2.04% |
| 2023 Q2 | 1.09 Billion SAR | -7.44% |
| 2023 Q1 | 1.18 Billion SAR | 1.52% |
| 2023 FY | 1.17 Billion SAR | 0.57% |
| 2023 Q4 | 1.17 Billion SAR | 7.01% |
| 2023 Q3 | 1.09 Billion SAR | 0.02% |
| 2022 Q4 | 1.16 Billion SAR | -11.93% |
| 2022 Q3 | 1.32 Billion SAR | 2.35% |
| 2022 Q2 | 1.29 Billion SAR | 0.31% |
| 2022 Q1 | 1.29 Billion SAR | -4.95% |
| 2022 FY | 1.16 Billion SAR | -14.05% |
| 2021 FY | 1.35 Billion SAR | 10.04% |
| 2021 Q3 | 1.28 Billion SAR | -4.4% |
| 2021 Q2 | 1.34 Billion SAR | 0.0% |
| 2021 Q1 | - SAR | -100.0% |
| 2021 Q4 | 1.35 Billion SAR | 5.99% |
| 2020 Q1 | - SAR | 0.0% |
| 2020 FY | 1.23 Billion SAR | 1.43% |
| 2020 Q4 | 828.95 Million SAR | 0.0% |
| 2019 FY | 1.21 Billion SAR | 0.0% |
| 2018 FY | - SAR | 0.0% |
| 2017 FY | - SAR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 59.77 Million SAR | -1865.146% |
| Al-Dawaa Medical Services Company | 2.29 Billion SAR | 48.796% |
| Al-Razi Medical Co. | 11.72 Million SAR | -9921.412% |
| Almujtama Alraida Medical Co. | 168.88 Million SAR | -595.592% |